Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans

Bausch Health Canada has announced that its product PrOKEDI 75 mg and 100 mg is now publicly reimbursed in seven provinces, including Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia, and Prince Edward Island, as well as through several federal drug plans. PrOKEDI is a prolonged-release injectable suspension of risperidone used for treating schizophrenia in adults, designed for a four-week dosing interval without the need for oral supplementation.